Exploring New Opportunities for Long-Term Controlled Drug Delivery

Long-acting controlled release is expanding to biologics and peptides. Join our experts to learn how.

Register Free: https://www.biopharminternational.com/bp_w/controlled-drug-delivery

Event Overview:

As therapies become more potent and complex, the pharmaceutical industry is seeking innovative drug delivery methods that improve patient outcomes and overcome the limits of conventional dosing. Long-acting, implantable polymer-based controlled-release systems represent an opportunity that extends beyond the applications where these technologies have traditionally been used. This panel will examine controlled-release delivery, for both small molecule and biologic drugs, including maintaining therapeutic exposure, reducing pharmacokinetic peaks and troughs, and improving compliance. They will also cover opportunities to extend these approaches to larger modalities like peptides, proteins, antibodies, and nucleic acids. Attendees will leave with a framework for identifying where controlled-release delivery may fit within their development pipeline.

Key Learning Objectives:

• Identify drug and therapeutic characteristics that may make a program well suited for long-term controlled-release delivery, including the potential benefits of maintaining more consistent therapeutic exposure.
• Evaluate key strategic considerations when assessing a controlled-release approach, including route of administration, treatment duration, drug potency, release kinetics and patient-compliance goals.
• Understand opportunities and challenges associated with extending controlled-release technologies beyond small molecules to peptides, proteins, antibodies and nucleic acids.
• Recognize emerging applications and delivery approaches that could expand the role of polymer-based controlled-release systems across therapeutic areas and drug-development programs.

Who Should Attend:

• VP/Director of Drug Delivery
• VP/Director of Formulation Development
• Head of Pharmaceutical Development
• Director of Device Engineering/Combination Products
• VP of R&D
• Formulation Scientist
• Process Development Engineer
• Director of CMC
• Regulatory Affairs Lead

Speakers:

Timothy Steckler, Ph.D.
Applications Technology Manager
NuSil

Dr. Timothy Steckler has a background in chemistry with a bachelor's degree from Winona State University in Minnesota and Ph.D. in organic chemistry with a focus on polymer chemistry from the University of Florida. This was followed by a postdoc at Chalmers University of Technology, Sweden where he furthered his organic and polymer chemistry knowledge.

Tim joined NuSil® over eleven years ago in the Process Engineering and Technical support group, bringing solid organic and polymer chemistry expertise. He then contributed to the NuSil product line in the Advanced Technologies Product Development group as a Technologist. As an Applications Engineer he combined his past experiences while working with customers to help targeted product development and provide continued technical support. Tim has been the Applications Technology Manger the past five years, whose group collaborates with customers to deliver novel specialty silicones.

Benny David, Ph.D.
Director, Global Business Development
NuSil

Dr. Benny David is a seasoned business and technology leader with extensive experience driving innovation, strategic growth, and commercialization in advanced materials and life sciences industries. Currently with NuSil®, a brand of Avantor®, he has built a career identifying emerging market opportunities and transforming innovative concepts into successful business initiatives. Benny combines deep technical expertise with strong business acumen, supported by his education at the Indian Institute of Technology Mumbai and Ph.D. from Technion - Israel Institute of Technology. He is recognized for fostering cross-functional collaboration, developing growth strategies, and delivering impactful results across global organizations.

Karl Malcolm
Professor, School of Pharmacy
Queens University, Belfast

Karl Malcolm is Professor of Drug Delivery in the School of Pharmacy at Queen's University Belfast. His internationally recognized research focuses on the development of sustained and controlled-release pharmaceutical products, with a particular emphasis on clinical applications in women's sexual and reproductive health. His work spans therapeutic areas including HIV/AIDS, contraception (both hormonal and non-hormonal), sexually transmitted infections, endometriosis, estrogen replacement therapy, and bacterial vaginosis.
Professor Malcolm has extensive expertise in drug-releasing vaginal ring technologies, multipurpose prevention technologies (MPTs), long-acting injectable formulations, drug-releasing subdermal and subcutaneous implants, and the development of polymers for medical devices and advanced drug delivery systems. His research has contributed significantly to the advancement of innovative long-acting therapies designed to improve patient outcomes and expand healthcare options for women worldwide.

Matthew Kihara
Sr. Manager, Global Market Strategy & Development
NuSil

Matthew Kihara is Senior Manager, Global Market Strategy and Development for the Medtech business at NuSil®, driving strategic growth initiatives and identifying emerging opportunities across the life sciences market. With more than a decade of experience in the silicone industry, he brings expertise spanning R&D, applications development, innovation, and commercial strategy. Since joining NuSil in 2021, Matthew has advanced through key technical and leadership roles, leveraging a strong background in materials science, polymer chemistry, and business development to support innovation and market expansion. He holds a Master's of Science in Industrial Polymer Chemistry and Materials Science from the University of Oregon and an MBA from Southern Utah University.

Register Free: https://www.biopharminternational.com/bp_w/controlled-drug-delivery